Close

Becton Dickinson (BDX) Reaction To FDA Letter Is Overblown - William Blair

March 19, 2019 8:27 AM EDT Send to a Friend
William Blair analyst Brian Weinstein reiterated an Outperform rating on Becton Dickinson (NYSE: BDX) despie the 3/15 FDA letter regarding ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login